New combo therapy targets Hard-to-Treat head and neck cancers
NCT ID NCT06919666
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 32 times
Summary
This study tests a new drug called NT219 combined with either pembrolizumab or cetuximab in people with head and neck cancer that has come back or spread. The goal is to see if these combinations can shrink tumors. The trial involves 29 adults whose cancer cannot be cured with standard treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
UCHealth Highlands Ranch Hospital
Highlands Ranch, Colorado, 80126, United States
-
Universtiy of Colorado Hospital
Aurora, Colorado, 80045, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.